Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions| Reviewers

Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 871    
     
ORIGINAL ARTICLE
Year : 2017  |  Volume : 7  |  Issue : 9  |  Page : 155-162

BRCA1/2 mutations in salivary pleomorphic adenoma and carcinoma-ex-pleomorphic adenoma


1 Department of Oral Pathology, Dental Research Center, Dental Faculty, Hamadan and Griffith University, School of Medicine, Gold Coast, Australia
2 Department of Pathology, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence Address:
Soussan Irani
Shahid Fahmide Blvd, Dental Faculty, Hamadan, Iran

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jispcd.JISPCD_184_17

Rights and Permissions

Objectives: It is hypothesized that carcinoma-ex-pleomorphic adenoma (Ca-ex-PA) is malignant from the beginning or is a malignant transformation of a recurrent or a long-standing pleomorphic adenoma (PA). The accumulation of genetic instabilities is suggested to be the main reason for malignant transformation in PA. The aim of this study was to determine the prevalence of BRCA1/2 mutations in PA and Ca-ex-PA. Materials and Methods: A total of ninety salivary gland tumors (45 Ca ex-PA and 45 PA) were selected. Immunohistochemistry was performed for all samples. Analyses were conducted through SPSS software version 22.0 (SPSS, Inc., Chicago, IL, USA). Chi-square test was used to examine the differences between the variables. Significant level was set at 0.05. Results: In general, 93.3% of PA samples showed positive staining for BRCA1 (in myoepithelial cells); however, BRCA2 positivity was found in 60% of samples (in myoepithelial cells). Among 45 samples of Ca-ex-PA, 93.3% of showed positivity for BRCA1 and 80% of samples showed positivity for BRCA2. Chi-square test found differences between PAs and Ca-ex-PAs regarding BRCA1/2 mutations in ductal cells and myoepithelial cells (P = 0.007, 0.000), respectively. Conclusions: The present study found a trend toward the presence of BRCA1/2 mutations in PA and Ca-ex-PA samples. Patients with BRCA1/2 mutation carriers are excellent cases for therapies, such as the poly (ADP) ribose polymerase inhibitor.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1128    
    Printed12    
    Emailed0    
    PDF Downloaded144    
    Comments [Add]    
    Cited by others 2    

Recommend this journal